Xtandi Japan Label Change Worth $45m To Medivation
This article was originally published in PharmAsia News
What’s the worth of words? Forty-five million dollars if you are Medivation, which will benefit from a milestone payment of that amount from partner Astellas Pharma in relation to a Japanese labeling change for prostate cancer drug Xtandi (enzalutamide).
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.